$22.74
0.98% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US92337R1014
Symbol
VERA
Sector
Industry

Vera Therapeutics Inc - Ordinary Shares - Class A Target price 2025 - Analyst rating & recommendation

Vera Therapeutics Inc - Ordinary Shares - Class A Classifications & Recommendation:

Buy
93%
Hold
7%

Vera Therapeutics Inc - Ordinary Shares - Class A Price Target

Target Price $64.00
Price $22.74
Potential
Number of Estimates 14
14 Analysts have issued a price target Vera Therapeutics Inc - Ordinary Shares - Class A 2026 . The average Vera Therapeutics Inc - Ordinary Shares - Class A target price is $64.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 13 Analysts recommend Vera Therapeutics Inc - Ordinary Shares - Class A to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vera Therapeutics Inc - Ordinary Shares - Class A stock has an average upside potential 2026 of . Most analysts recommend the Vera Therapeutics Inc - Ordinary Shares - Class A stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -2.75 -3.38
22.22% 22.91%
P/E negative

7 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast for earnings per share. The average Vera Therapeutics Inc - Ordinary Shares - Class A EPS is

$-3.38
Unlock
. This is
22.91% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.79 1.45%
Unlock
, the lowest is
$-3.94 43.27%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.75 22.22%
2025
$-3.38 22.91%
Unlock
2026
$-3.72 10.06%
Unlock
2027
$-3.31 11.02%
Unlock
2028
$-0.79 76.13%
Unlock
2029
$2.14 370.89%
Unlock

P/E ratio

Current -8.27 60.48%
2025
-6.72 18.73%
Unlock
2026
-6.11 9.08%
Unlock
2027
-6.88 12.60%
Unlock
2028
-28.88 319.77%
Unlock
2029
10.63 136.81%
Unlock

Current Vera Therapeutics Inc - Ordinary Shares - Class A Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Scotiabank
Locked
Locked
Locked Jun 02 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 02 2025
Wedbush
Locked
Locked
Locked May 07 2025
Cantor Fitzgerald
Locked
Locked
Locked May 07 2025
JP Morgan
Locked
Locked
Locked Mar 04 2025
Guggenheim
Locked
Locked
Locked Feb 27 2025
Wolfe Research
Locked
Locked
Locked Feb 04 2025
Analyst Rating Date
Locked
Scotiabank:
Locked
Locked
Jun 02 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 02 2025
Locked
Wedbush:
Locked
Locked
May 07 2025
Locked
Cantor Fitzgerald:
Locked
Locked
May 07 2025
Locked
JP Morgan:
Locked
Locked
Mar 04 2025
Locked
Guggenheim:
Locked
Locked
Feb 27 2025
Locked
Wolfe Research:
Locked
Locked
Feb 04 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today